Stockscreener 앱 받기
5.56
2.77%
0.15
시장 영업 전:
5.56
Imagenebio Inc 주식(IMA)의 최신 뉴스
IMA,CVRX Volatility & Greeks - Finviz
IMA,CVRX Dividends - Finviz
ImageneBio (IMA) CEO receives 128,100 options and 85,400 RSUs - Stock Titan
ImageneBio Announces Leadership Transition in Finance Organization - The Globe and Mail
ImageneBio Approves Inducement Grants for New Employees Under Nasdaq Rule 5635(c)(4) - geneonline.com
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
ImageneBio, Inc. Announces Principal Accounting Officer Changes, Effective March 20, 2026 - marketscreener.com
ImageneBio (NASDAQ: IMA) names Bob Lally Principal Accounting Officer as Erin Butler departs - Stock Titan
Two new ImageneBio hires get four-year stock incentive grants - Stock Titan
Atlas Venture Buys Stake in Biotech Firm ImageneBio - National Today
Atlas Venture Life Science Advisors LLC Buys New Position in ImageneBio, Inc. $IMA - Defense World
Wall Street Zen Upgrades ImageneBio (NASDAQ:IMA) to "Hold" - MarketBeat
IMA,CVRX Options - Finviz
Legal and Regulatory Risks: How Litigation and Government Actions Could Impact Imagenebio, Inc.’s Financial Performance - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), ImageneBio (IMA) - The Globe and Mail
ImageneBio, Inc. 2025 10-K: IMG-007 Clinical Development, Strategy, and Market Opportunities in Immunological Diseases - Minichart
ImageneBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ImageneBio 10-K: License revenue $0.8M; Net loss $45.3M - TradingView
ImageneBio (NASDAQ: IMA) bets on OX40 antibody IMG-007 after Ikena merger - Stock Titan
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update - The Manila Times
ImageneBio eczema antibody tested in 150+ people without malignancies to date - Stock Titan
Blue Owl Capital Holdings LP Purchases New Stake in ImageneBio, Inc. $IMA - MarketBeat
ImageneBio Inc expected to post a loss of $1.45 a shareEarnings Preview - TradingView
IMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
IMA,CVRX Revenue Breakdown - Finviz
ImageneBio to Participate in Leerink Global Healthcare Conference - Eagle-Tribune
BML Capital Management LLC Makes New Investment in ImageneBio, Inc. $IMA - Defense World
ImageneBio (NASDAQ:IMA) Shares Up 2.4% – Still a Buy? - Defense World
ImageneBio announces immediate resignation of board director - TipRanks
ImageneBio (NASDAQ: IMA) prospectus supplement updates resale of 2.5M shares - Stock Titan
ImageneBio, Inc. Announces Resignation of Steven Hui Wang as Member of the Board of Directors, Effective on February 12, 2026 - marketscreener.com
ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer By Investing.com - Investing.com Nigeria
ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer - Investing.com South Africa
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer - marketscreener.com
New ImageneBio CMO to lead late-stage eczema trial using OX40 drug - Stock Titan
ImageneBio Debuts on Nasdaq Following Merger Completion - AD HOC NEWS
ImageneBio (NASDAQ:IMA) Trading Up 0.5%Should You Buy? - MarketBeat
ImageneBio, Inc. (NASDAQ:IMA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Joseph Slattery Spends US$96k On ImageneBio Stock - simplywall.st
ImageneBio Insider Confidence Rewarded, Stock Hits US$76m Market Cap - Yahoo Finance
Top ImageneBio Insider Makes Bold New Move on Company Stock - TipRanks
Joseph Slattery Buys 16,000 Shares of ImageneBio (NASDAQ:IMA) Stock - MarketBeat
ImageneBio chief medical officer resigns, transition planned - MSN
ImageneBio Chief Medical Officer Resigns, Transition Planned - TipRanks
ImageneBio, Inc. Announces Resignation of Yufang Lu as Chief Medical Officer, effective December 31, 2025 - marketscreener.com
1.82%
자본화:
|
볼륨(24시간):